KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice

Journal of Clinical Investigation

Volumn 118, Issue 12, 2008, Pages 3848-3859

  Langenickel, Thomas H ^a   Olive, Michelle ^a   Boehm, Manfred ^a   San, Hong ^a   Crook, Martin F ^a   Nabel, Elizabeth G ^a,b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN KINASE; PROTEIN KIS; STATHMIN; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; INTIMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VASCULAR SMOOTH MUSCLE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; STATHMIN; TUNICA MEDIA; WOUND HEALING;

EID: 57449094455     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33206     Document Type: Article

References (31)

1. Boehm, M., et al. 2004. Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism. J. Clin. Invest. 114:419-426.
2. Maucuer, A., Camonis, J.H., and Sobel, A. 1995. Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. Proc. Natl. Acad. Sci. U. S. A. 92:3100-3104.
3. Boehm, M., et al. 2002. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J. 21:3390-3401.
4. Maucuer, A., et al. 1997. KIS is a protein kinase with an RNA recognition motif. J. Biol. Chem. 272:23151-23156.
5. Maucuer, A., Le Caer, J.P., Manceau, V., and Sobel, A. 2000. Specific Ser-Pro phosphorylation by the RNA-recognition motif containing kinase KIS. Eur. J. Biochem. 267:4456-4464.
6. Polyak, K., et al. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:59-66.
7. Sherr, C.J., and Roberts, J.M. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
8. Belmont, L.D., and Mitchison, T.J. 1996. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell. 84:623-631.
9. Howell, B., Larsson, N., Gullberg, M., and Cassimeris, L. 1999. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. Mol. Biol. Cell. 10:105-118.
10. Labdon, J.E., Nieves, E., and Schubart, U.K. 1992. Analysis of phosphoprotein p19 by liquid chromatography/ mass spectrometry. Identification of two proline-directed serine phosphorylation sites and a blocked amino terminus. J. Biol. Chem. 267:3506-3513.
11. Beretta, L., Dobransky, T., and Sobel, A. 1993. Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J. Biol. Chem. 268:20076-20084.
12. Di Paolo, G., Antonsson, B., Kassel, D., Riederer, B.M., and Grenningloh, G. 1997. Phosphorylation regulates the microtubule-destabilizing activity of stathmin and its interaction with tubulin. FEBS Lett. 416:149-152.
13. Marklund, U., Osterman, O., Melander, H., Bergh, A., and Gullberg, M. 1994. The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control. J. Biol. Chem. 269:30626-30635.
14. Brattsand, G., Marklund, U., Nylander, K., Roos, G., and Gullberg, M. 1994. Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38. Eur. J. Biochem. 220:359-368.
15. Larsson, N., Melander, H., Marklund, U., Osterman, O., and Gullberg, M. 1995. G2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct protein kinase systems. J. Biol. Chem. 270:14175- 14183.
16. Baldassarre, G., et al. 2005. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 7:51-63.
17. Jin, K., et al. 2004. Proteomic and immunochemical characterization of a role for stathmin in adult neurogenesis. FASEB J. 18:287-299.
18. Liedtke, W., Leman, E.E., Fyffe, R.E., Raine, C.S., and Schubart, U.K. 2002. Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems. Am. J. Pathol. 160:469-480.
19. Shumyatsky, G.P., et al. 2005. Stathmin, a gene enriched in the amygdala, controls both learned and innate fear. Cell. 123:697-709.
20. Giampietro, C., et al. 2005. Stathmin expression modulates migratory properties of GN-11 neurons in vitro. Endocrinology. 146:1825- 1834.
21. Ng, D.C., et al. 2006. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell Biol. 172:245-257.
22. Grube, E., et al. 2005. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am. J. Cardiol. 96:79-82.
23. Grube, E., et al. 2003. TAXUS I: six- and twelvemonth results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 107:38-42.
24. Tanabe, K., et al. 2003. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 107:559-564.
25. Turco, M.A., et al. 2007. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J. Am. Coll. Cardiol. 49:1676-1683.
26. Weissman, N.J., et al. 2005. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J. Am. Coll. Cardiol. 45:1201-1205.
27. Deng, X., Mercer, S.E., Shah, S., Ewton, D.Z., and Friedman, E. 2004. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J. Biol. Chem. 279:22498-22504.
28. Kawauchi, T., Chihama, K., Nabeshima, Y., and Hoshino, M. 2006. Cdk5 phosphorylates and stabilizes p27kip1 contributing to actin organization and cortical neuronal migration. Nat. Cell. Biol. 8:17-26.
29. Grimmler, M., et al. 2007. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 128:269-280.
30. Chu, I., et al. 2007. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 128:281-294.
31. Farb, A., Weber, D.K., Kolodgie, F.D., Burke, A.P., and Virmani, R. 2002. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 105:2974-2980.